Literature DB >> 21864546

Is there evidence of involvement of DNA repair polymorphisms in human cancer?

Fulvio Ricceri1, Giuseppe Matullo, Paolo Vineis.   

Abstract

DNA suffers from a wide range of damage, both from extracellular agents and via endogenous mechanisms. Damage of DNA can lead to cancer and other diseases. Therefore, it is plausible that sequence variants in DNA repair genes are involved in cancer development. A recent systematic review and meta-analysis, based on the "Venice criteria", showed that out of 241 associations investigated, only three resulted to have a strong grade of cumulative evidence. These associations were: two SNPs rs1799793 and rs13181 in the ERCC2 gene and lung cancer (recessive model) and rs1805794 in the NBN gene and bladder cancer (dominant model). An update of this meta-analysis has been performed in the present paper, and we found partially inconsistent results. Inconsistencies in the literature are thus far not easy to explain. In addition, none of the cancer genome-wide association studies (GWAs) published so far showed highly statistically significant associations for any of the common DNA repair gene variants, in such a way as to place DNA repair genes among the top 10-20 hits identified in GWAs. Though this suggests that it is unlikely that DNA repair gene polymorphisms per se play a major role, a clarification of the discrepancies in the literature is needed. Also, gene/environment and gene/lifestyle interactions for the carcinogenic mechanisms involving DNA repair should be investigated more systematically and with less classification error. Finally, the combined effect of multiple SNPs in several genes in one or more relevant DNA repair pathways could have a greater impact on pathological phenotypes than SNPs in single genes, but this has been investigated only occasionally.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21864546     DOI: 10.1016/j.mrfmmm.2011.07.013

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  23 in total

1.  DNA repair gene variants in endometrial carcinoma.

Authors:  Zeynep Birsu Cincin; Ahmet Cem Iyibozkurt; Sibel Bulgurcuoglu Kuran; Bedia Cakmakoglu
Journal:  Med Oncol       Date:  2012-01-22       Impact factor: 3.064

2.  Predicted for greatness: 1994 molecule of the year--the DNA repair enzyme.

Authors:  Marianne Berwick
Journal:  Cancer Prev Res (Phila)       Date:  2014-03-20

3.  DNA repair genes polymorphism and lung cancer risk with the emphasis to sex differences.

Authors:  L Letkova; T Matakova; L Musak; M Sarlinova; M Krutakova; P Slovakova; E Kavcova; V Jakusova; M Janickova; A Drgova; P Berzinec; E Halasova
Journal:  Mol Biol Rep       Date:  2013-05-15       Impact factor: 2.316

4.  Genetic variant in DNA repair gene GTF2H4 is associated with lung cancer risk: a large-scale analysis of six published GWAS datasets in the TRICL consortium.

Authors:  Meilin Wang; Hongliang Liu; Zhensheng Liu; Xiaohua Yi; Heike Bickeboller; Rayjean J Hung; Paul Brennan; Maria Teresa Landi; Neil Caporaso; David C Christiani; Jennifer Anne Doherty; Christopher I Amos; Qingyi Wei
Journal:  Carcinogenesis       Date:  2016-06-10       Impact factor: 4.944

Review 5.  Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer.

Authors:  Shanbeh Zienolddiny; Vidar Skaug
Journal:  Lung Cancer (Auckl)       Date:  2011-12-29

6.  Polymorphisms of the XPC gene may contribute to the risk of head and neck cancer: a meta-analysis.

Authors:  Yang Zhang; Zufei Li; Qi Zhong; Weiguo Zhou; Xuejun Chen; Xiaohong Chen; Jugao Fang; Zhigang Huang
Journal:  Tumour Biol       Date:  2013-12-13

7.  DNA repair gene variants in relation to overall cancer risk: a population-based study.

Authors:  Anthony J Alberg; Timothy J Jorgensen; Ingo Ruczinski; Lee Wheless; Yin Yao Shugart; Yvette Berthier-Schaad; Bailey Kessing; Judith Hoffman-Bolton; Kathy J Helzlsouer; W H Linda Kao; Lesley Francis; Rhoda M Alani; Michael W Smith; Paul T Strickland
Journal:  Carcinogenesis       Date:  2012-10-01       Impact factor: 4.944

8.  Pharmacogenetic association between XRCC1 polymorphisms and improved outcomes in bladder cancer patients following intravesical instillation of epirubicin.

Authors:  Pengchao Li; Xiaolei Zhang; Xiaheng Deng; Jun Tao; Chao Qin; Xiao Yang; Yidong Cheng; Qiang Lu; Zengjun Wang; Changjun Yin
Journal:  Int J Clin Exp Med       Date:  2015-07-15

9.  Association between XPD Lys751Gln polymorphism and bladder cancer susceptibility: an updated and cumulative meta-analysis based on 6,836 cases and 8,251 controls.

Authors:  Sheng Li; Xian Tao Zeng; Xiao Lan Ruan; Tong Zu Liu; Xing Huan Wang
Journal:  Mol Biol Rep       Date:  2014-02-08       Impact factor: 2.316

10.  Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treated with chemotherapy.

Authors:  Carlotta Sacerdote; Simonetta Guarrera; Fulvio Ricceri; Barbara Pardini; Silvia Polidoro; Alessandra Allione; Rossana Critelli; Alessia Russo; Angeline S Andrew; Yuanqing Ye; Xifeng Wu; Lambertus A Kiemeney; Andrea Bosio; Giovanni Casetta; Giuseppina Cucchiarale; Paolo Destefanis; Paolo Gontero; Luigi Rolle; Andrea Zitella; Dario Fontana; Paolo Vineis; Giuseppe Matullo
Journal:  Int J Cancer       Date:  2013-04-25       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.